|
CD4 <200/μL
| CD4 ≧200/μL |
P value
|
CD4 <200/μL
| CD4 ≧200/μL |
P value
| |
Patient number, n
|
211
|
68
| |
145
|
71
| |
165
|
Age at enrollment, mean (SD), y
|
39.0 (12.0)
|
35.0 (10.7)
|
0.03
|
38.6 (10.2)
|
35.0 (8.4)
|
0.006
|
37.0 (10.9)
|
Male sex, n (%)
|
195 (92.4)
|
66 (97.1)
|
0.26
|
134 (92.4)
|
68 (95.8)
|
0.56
|
152 (92.1)
|
Risk behaviors, no (%)
| | | | | | | |
MSM
|
138 (65.4)
|
48 (70.6)
|
0.74
|
89 (61.4)
|
58 (81.7)
|
0.22
|
110 (66.7)
|
Heterosexual
|
68 (32.2)
|
17 (25.0)
|
0.47
|
50 (34.5)
|
10 (14.1)
|
0.02
|
41 (24.8)
|
Others
|
5 (2.4)
|
3 (4.4)
|
0.41
|
6 (4.1)
|
3 (4.2)
|
0.99
|
14 (8.5)
|
Nadir CD4 count, median (range), cells/μL
|
27 (1-182)
|
93 (67-194)
|
<0.001
|
17 (0-165)
|
40 (1-174)
|
<0.001
|
134 (4-199)
|
Baseline PVL, median (range), log10 copies/ml
|
5.46 (2.60-6.12)
|
5.60 (2.60-6.19)
|
0.13
|
5.56 (2.60-5.99)
|
5.72 (3.09-5.98)
|
0.04
|
5.14 (2.60-5.88)
|
Chemoprophylaxis, n (%)
| | | | | | | |
Trimethoprim-sulfamethoxazole
|
207 (98.1)
|
67 (98.5)
|
1
|
142 (97.9)
|
71 (100)
|
1
|
NA
|
Clindamycin/primaquine
|
2 (0.9)
|
2 (2.9)
|
0.26
|
29 (20.0)
|
15 (21.1)
|
0.86
|
NA
|
Macrolides
|
16 (9.0)
|
5 (7.4)
|
1
|
6 (4.1)
|
7 (9.9)
|
0.14
|
NA
|
Duration of prophylaxis, median (range), m
|
2.0 (0.2-66.2)
|
5.3 (0.25-47.8)
|
0.036
|
2.7 (0.1-62)
|
4.0 (0.34-57)
|
0.04
| |
CD4 at discontinuation of prophylaxis
| | | | | | | |
median (range), cells/ul
|
101 (2-199)
|
234 (207-642)
|
<0.001
|
111 (5-197)
|
279 (201-880)
|
<0.001
| |
<100 cells/ul, n (%)
|
101 (47.9)
|
0 (0)
| |
53 (36.6)
|
0 (0)
| | |
PVL at discontinuation of prophylaxis, median (range), log10 copies/ml
|
2.60 (2.60-5.88)
|
2.60 (2.60-5.15)
|
0.027
|
2.60 (2.60-5.88)
|
2.60 (2.60-5.51)
|
0.022
|
NA
|
PVL < 400 copies/ml, no (%)
|
130 (61.6)
|
55 (80.9)
|
0.24
|
85 (58.6)
|
53 (74.6)
|
0.31
|
NA
|
Latest CD4, median (range), cells/ul
|
200 (2-214)
|
376 (0-952)
|
0.019
|
200 (2-215)
|
426 (2-1124)
|
0.005
|
200 (4-209)
|
<200 cells/ul, n (%)
|
78 (37.0)
|
15 (22)
|
0.11
|
41 (28.3)
|
10 (14.1)
|
0.09
|
49 (29.7)
|